What do systematic reviews say?

Mental practice vs conventional therapy

• Mental practice for treating upper extremity deficits in individuals with hemiparesis after stroke 2020 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

Mental practice vs conventional therapy

• Mental practice for treating upper extremity deficits in individuals with hemiparesis after stroke 2020 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 50 participants
  Low

Mental practice vs conventional therapy

• Mental practice for treating upper extremity deficits in individuals with hemiparesis after stroke 2020 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

Oscillating devices vs conventional physiotherapy

• Oscillating devices for airway clearance in people with cystic fibrosis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  10 studies · 363 participants
  Very low

Oscillating devices vs conventional physiotherapy

• Oscillating devices for airway clearance in people with cystic fibrosis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  8 studies · 319 participants
  Very low

Oscillating devices vs conventional physiotherapy

• Oscillating devices for airway clearance in people with cystic fibrosis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  7 studies · 268 participants
  Very low

Oscillating devices vs conventional physiotherapy

• Oscillating devices for airway clearance in people with cystic fibrosis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 17 participants
  Low

Oscillating devices vs conventional physiotherapy

• Oscillating devices for airway clearance in people with cystic fibrosis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  8 studies · 188 participants
  Very low

Oscillating devices vs conventional physiotherapy

• Oscillating devices for airway clearance in people with cystic fibrosis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 262 participants
  Very low

Oscillating devices vs conventional physiotherapy

• Oscillating devices for airway clearance in people with cystic fibrosis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  9 studies · 345 participants
  Very low

Vitamin A and fish oils (docosahexaenoic acid) vs placebo, vitamins, or no treatment

• Vitamin A and fish oils for preventing the progression of retinitis pigmentosa 2020 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 881 participants
  Very low

Vitamin A and fish oils (docosahexaenoic acid) vs placebo, vitamins, or no treatment

It is very uncertain whether vitamin A and fish oils (docosahexaenoic acid) changes visual acuitychange in logMAR visual acuity, may be reported as ETDRS compared with placebo, vitamins (including vitamin A), or no therapy (very low certainty).

• Vitamin A and fish oils for preventing the progression of retinitis pigmentosa 2020 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 881 participants
  Very low

Vitamin A and fish oils (docosahexaenoic acid) vs placebo, vitamins, or no treatment

• Vitamin A and fish oils for preventing the progression of retinitis pigmentosa 2020 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 881 participants
  Very low

Vitamin A and fish oils (docosahexaenoic acid) vs placebo, vitamins, or no treatment

• Vitamin A and fish oils for preventing the progression of retinitis pigmentosa 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 51 participants
  Very low

Vitamin A and fish oils (docosahexaenoic acid) vs placebo, vitamins, or no treatment

• Vitamin A and fish oils for preventing the progression of retinitis pigmentosa 2020 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 944 participants
  Very low

Carboplatin vs cisplatin chemotherapy

Carboplatin showed no clear difference in overall survival (baseline risks for low‐ and high‐risk groups in… compared with cisplatin chemotherapy (high certainty).

• Cisplatin versus carboplatin in combination with third‐generation drugs for advanced non‐small cell lung cancer 2020 · Cochrane Headline outcomes only
  HR 0.99 [0.82, 1.2]
  10 studies · 2515 participants
  High

Carboplatin vs cisplatin chemotherapy

Carboplatin showed no clear difference in 1‐year survival rate compared with cisplatin chemotherapy (high certainty).

• Cisplatin versus carboplatin in combination with third‐generation drugs for advanced non‐small cell lung cancer 2020 · Cochrane Headline outcomes only
  RR 0.98 [0.89, 1.08]
  11 studies · 4004 participants
  High

Carboplatin vs cisplatin chemotherapy

Carboplatin showed no clear difference in response rate compared with cisplatin chemotherapy (high certainty).

• Cisplatin versus carboplatin in combination with third‐generation drugs for advanced non‐small cell lung cancer 2020 · Cochrane Headline outcomes only
  RR 0.89 [0.79, 1]
  11 studies · 4020 participants
  High

Carboplatin vs cisplatin chemotherapy

Carboplatin probably leads to higher grade III or IV neurotoxicity compared with cisplatin chemotherapy (moderate certainty).

• Cisplatin versus carboplatin in combination with third‐generation drugs for advanced non‐small cell lung cancer 2020 · Cochrane Headline outcomes only
  RR 1.42
  10 studies · 3857 participants
  Moderate

Carboplatin vs cisplatin chemotherapy

Carboplatin probably leads to higher grade III or IV thrombocytopenia compared with cisplatin chemotherapy (moderate certainty).

• Cisplatin versus carboplatin in combination with third‐generation drugs for advanced non‐small cell lung cancer 2020 · Cochrane Headline outcomes only
  RR 2.46 [1.49, 4.04]
  10 studies · 3857 participants
  Moderate